Karina Kulangara
- Cell Biology top 2%
- Cellular Mechanics and Interactions 6
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 11
- Colorectal Cancer Treatments and Studies 3
- Biomedical Engineering top 5%
- 3D Printing in Biomedical Research 8
- Biomaterials top 5%
- Surfaces, Coatings and Films top 5%
-
- Radiomics and Machine Learning in Medical Imaging 10
-
- Neuroscience and Neuropharmacology Research 4
- Neuroscience and Neural Engineering 3
-
- Lipid Membrane Structure and Behavior 3
- Co-authors
- Kam W. LeongFarshid GuilakEric M. DarlingEvelyn K. F. YimYong YangKenneth EmancipatorTania Rinaldi BarkatHenry Markram
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Karina Kulangara
32 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Cell Biology 628
- Oncology 726
- Biomedical Engineering 927
- Biomaterials 273
- Surfaces, Coatings and Films 126
Countries citing papers authored by Karina Kulangara
This map shows the geographic impact of Karina Kulangara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karina Kulangara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karina Kulangara more than expected).
Fields of papers citing papers by Karina Kulangara
This network shows the impact of papers produced by Karina Kulangara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karina Kulangara. The network helps show where Karina Kulangara may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Karina Kulangara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2021 | 2 | |
| 3 | 2021 | 1 | |
| 4 | Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancerbreakdown → | 2018 | 378 |
| 5 | 2016 | 249 | |
| 6 | 2014 | 27 | |
| 7 | 2014 | 80 | |
| 8 | 2012 | 122 | |
| 9 | 2012 | 53 | |
| 10 | 2011 | 115 | |
| 11 | 2011 | 8 | |
| 12 | 2011 | 56 | |
| 13 | 2010 | 64 | |
| 14 | Nanotopography-induced changes in focal adhesions, cytoskeletal organization, and mechanical properties of human mesenchymal stem cellsbreakdown → | 2009 | 571 |
| 15 | 2008 | 11 | |
| 16 | 2007 | 15 | |
| 17 | 2005 | 38 | |
| 18 | 2005 | 92 | |
| 19 | 2004 | 74 | |
| 20 | Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. | 2003 | 80 |
About Karina Kulangara
Karina Kulangara is a scholar working on Cell Biology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 32 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Radiomics and Machine Learning in Medical Imaging (10 papers), 3D Printing in Biomedical Research (8 papers), Cellular Mechanics and Interactions (6 papers), Neuroscience and Neuropharmacology Research (4 papers), Lipid Membrane Structure and Behavior (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Neuroscience and Neural Engineering (3 papers). The work is most often cited by research in Cell Biology (628 citations), Oncology (726 citations) and Biomedical Engineering (927 citations). Karina Kulangara has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Kam W. Leong, Farshid Guilak, Eric M. Darling, Evelyn K. F. Yim, Yong Yang, Kenneth Emancipator, Tania Rinaldi Barkat, Henry Markram, Malinka Jansson and Ellie Corigliano.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.